
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is a global leader in the medical device industry and has a strong portfolio of products in various segments. With reported revenue and earnings growth, the company is poised for future success through product launches and investments. However, competitors, supply chain disruptions, and geopolitical concerns could present challenges to their growth plans. Overall, Boston Scientific is well-positioned but faces potential risks in the competitive market.
Bears say
Boston Scientific is facing several headwinds that may negatively impact their revenue growth and earnings per share (EPS) forecast, leading me to have a negative outlook on the company's stock. Management lowered their 2026 revenue growth guidance from 10.5-11.5% to 7.0-8.5% and organic revenue growth guidance from 10.0-11.0% to 6.5-8.0%, while also lowering EPS guidance, signaling potential challenges and slower growth ahead. Additionally, the company is facing competitive pressures in certain segments, such as Urology and CRM, and has experienced disruptions in supply chain and business operations. These factors may limit the company's ability to achieve its long-term revenue and earnings targets. Furthermore, the recent announcement of a $2 billion buyback may not be enough to offset these headwinds and drive significant shareholder returns in the short term.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares